IPilogue

FEBRUARY 2, 2022

As part of the Osgoode Intellectual Property Law & Technology Intensive Program, I had the wonderful opportunity of completing a 10-week internship at AstraZeneca Canada (“AstraZeneca”). As a multinational pharmaceutical company, AstraZeneca is often involved in complex patent litigation.

Business 106

Business Privacy Intellectual Property Law Advertising 106

IPilogue

JANUARY 9, 2023

This term, I had the amazing opportunity to work at AstraZeneca Canada through Osgoode’s Intellectual Property Law and Technology Intensive Program placement. The event started with the CEO’s opening address reflecting on AstraZeneca’s growth over the last few years. This article was written as a requirement for Prof.

Business 110

Business Privacy Contracts Confidentiality 110

SpicyIP

JULY 26, 2021

Topical Highlight. The Delhi High Court in Astrazeneca Ab v. Fear Won’t Take You Anywhere: Delhi HC Revisits Bolar Exception, Rules Apprehensions Cannot Deny Liberty under Section 107A. Decisions from Indian Courts.

Copyright 97

Copyright Patent Television Intellectual Property 97

IPilogue

SEPTEMBER 3, 2021

We are pleased to welcome our returning placement organizations: Alectra Utilities, AstraZeneca Canada Inc., We are pleased to welcome our returning placement organizations: Alectra Utilities, AstraZeneca Canada Inc., Professor David Vaver will be the Director of the IP Intensive program this year.

IP 81

IP Intellectual Property Intellectual Property Law Patent Application 81

SpicyIP

FEBRUARY 12, 2024

Last week we published 9 posts on topics such as our comments on the proposed Trademarks (1st Amendment) Rules, the Madras High Court’s decision with respect to patentability of business methods, and Union Minister of State for Commerce’s response on ability of the current IPR regime to cater concerns arising out of AI generated work.

Trademark 103

Trademark Social Media Registering Trademarks Copyright 103

Fish & Richardson Trademark & Copyright Thoughts

JANUARY 11, 2022

The letter discusses the BPCIA and the Hatch-Waxman Act frameworks (for small molecule drugs) and sets forth several topics for USPTO’s consideration and further discussion: engagement between FDA and USPTO to increase efficiencies, possible misuse of the patent system (e.g., and AstraZeneca Pharmaceuticals, LP brought against SeaGen, Inc.

Litigation 52

Litigation Settlement Patent Marketing 52